약물 및 유전자 전달 시스템 시장 : 세계 산업 분석, 규모, 점유율, 수량, 성장, 동향 및 예측(2023-2031년)

Drug and Gene Delivery Systems Market - Scope of Report

TMR's report on the global drug and gene delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug and gene delivery systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug and gene delivery systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug and gene delivery systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug and gene delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug and gene delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug and gene delivery systems market.

The report delves into the competitive landscape of the global drug and gene delivery systems market. Key players operating in the global drug and gene delivery systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug and gene delivery systems market profiled in this report.

Key Questions Answered in Global drug and gene delivery systems Market Report:

• What is the sales/revenue generated by drug and gene delivery systems across all regions during the forecast period?
• What are the opportunities in the global drug and gene delivery systems market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Drug and Gene Delivery Systems Market - Research Objectives and Research Approach

The comprehensive report on the global drug and gene delivery systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug and gene delivery systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug and gene delivery systems market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug and Gene Delivery Systems Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Delivery System Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Delivery System/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Delivery System, 2017-2031
  • 6.3.1. Drug Delivery Systems
    • 6.3.1.1. Intrauterine Implants
    • 6.3.1.2. Prodrug Implants
    • 6.3.1.3. Polymeric Drug Delivery
    • 6.3.1.4. Targeted Drug Delivery
  • 6.3.2. Gene Delivery Systems
    • 6.3.2.1. Viral Gene Delivery
      • 6.3.2.1.1. Adenovirus Vector
      • 6.3.2.1.2. Lentivirus Vector
      • 6.3.2.1.3. Retrovirus Vector
      • 6.3.2.1.4. Adeno-associated Virus Vector
      • 6.3.2.1.5. Sendai Virus Vector
      • 6.3.2.1.6. Herpes Simplex Virus Vector
      • 6.3.2.1.7. Others
    • 6.3.2.2. Non-viral Gene Delivery
      • 6.3.2.2.1. Natural Organic Compounds
      • 6.3.2.2.2. Physical Methods
      • 6.3.2.2.3. Chemical Methods
    • 6.3.2.3. Combined Hybrid System
• 6.4. Market Attractiveness Analysis, by Delivery System

7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Route of Administration, 2017-2031
  • 7.3.1. Oral
  • 7.3.2. Injectable
  • 7.3.3. Inhalation
  • 7.3.4. Transdermal
  • 7.3.5. Ocular
  • 7.3.6. Nasal
  • 7.3.7. Topical
• 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Application, 2017-2031
  • 8.3.1. Infectious Diseases
  • 8.3.2. Oncology
  • 8.3.3. Ophthalmology
  • 8.3.4. Urology
  • 8.3.5. Diabetes
  • 8.3.6. CNS
  • 8.3.7. Others
• 8.4. Market Attractiveness Analysis, by Application

9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2017-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Drug and Gene Delivery Systems Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Delivery System, 2017-2031
  • 10.3.1. Drug Delivery Systems
    • 10.3.1.1. Intrauterine Implants
    • 10.3.1.2. Prodrug Implants
    • 10.3.1.3. Polymeric Drug Delivery
    • 10.3.1.4. Targeted Drug Delivery
  • 10.3.2. Gene Delivery Systems
    • 10.3.2.1. Viral Gene Delivery
      • 10.3.2.1.1. Adenovirus Vector
      • 10.3.2.1.2. Lentivirus Vector
      • 10.3.2.1.3. Retrovirus Vector
      • 10.3.2.1.4. Adeno-associated Virus Vector
      • 10.3.2.1.5. Sendai Virus Vector
      • 10.3.2.1.6. Herpes Simplex Virus Vector
      • 10.3.2.1.7. Others
    • 10.3.2.2. Non-viral Gene Delivery
      • 10.3.2.2.1. Natural Organic Compounds
      • 10.3.2.2.2. Physical Methods
      • 10.3.2.2.3. Chemical Methods
    • 10.3.2.3. Combined Hybrid System
• 10.4. Market Value Forecast, by Route of Administration, 2017-2031
  • 10.4.1. Oral
  • 10.4.2. Injectable
  • 10.4.3. Inhalation
  • 10.4.4. Transdermal
  • 10.4.5. Ocular
  • 10.4.6. Nasal
  • 10.4.7. Topical
• 10.5. Market Value Forecast, by Application, 2017-2031
  • 10.5.1. Infectious Diseases
  • 10.5.2. Oncology
  • 10.5.3. Ophthalmology
  • 10.5.4. Urology
  • 10.5.5. Diabetes
  • 10.5.6. CNS
  • 10.5.7. Others
• 10.6. Market Value Forecast, by Country, 2017-2031
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Delivery System
  • 10.7.2. By Route of Administration
  • 10.7.3. By Application
  • 10.7.4. By Country

11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Delivery System, 2017-2031
  • 11.3.1. Drug Delivery Systems
    • 11.3.1.1. Intrauterine Implants
    • 11.3.1.2. Prodrug Implants
    • 11.3.1.3. Polymeric Drug Delivery
    • 11.3.1.4. Targeted Drug Delivery
  • 11.3.2. Gene Delivery Systems
    • 11.3.2.1. Viral Gene Delivery
      • 11.3.2.1.1. Adenovirus Vector
      • 11.3.2.1.2. Lentivirus Vector
      • 11.3.2.1.3. Retrovirus Vector
      • 11.3.2.1.4. Adeno-associated Virus Vector
      • 11.3.2.1.5. Sendai Virus Vector
      • 11.3.2.1.6. Herpes Simplex Virus Vector
      • 11.3.2.1.7. Others
    • 11.3.2.2. Non-viral Gene Delivery
      • 11.3.2.2.1. Natural Organic Compounds
      • 11.3.2.2.2. Physical Methods
      • 11.3.2.2.3. Chemical Methods
    • 11.3.2.3. Combined Hybrid System
• 11.4. Market Value Forecast, by Route of Administration, 2017-2031
  • 11.4.1. Oral
  • 11.4.2. Injectable
  • 11.4.3. Inhalation
  • 11.4.4. Transdermal
  • 11.4.5. Ocular
  • 11.4.6. Nasal
  • 11.4.7. Topical
• 11.5. Market Value Forecast, by Application, 2017-2031
  • 11.5.1. Infectious Diseases
  • 11.5.2. Oncology
  • 11.5.3. Ophthalmology
  • 11.5.4. Urology
  • 11.5.5. Diabetes
  • 11.5.6. CNS
  • 11.5.7. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Delivery System
  • 11.7.2. By Route of Administration
  • 11.7.3. By Application
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Delivery System, 2017-2031
  • 12.3.1. Drug Delivery Systems
    • 12.3.1.1. Intrauterine Implants
    • 12.3.1.2. Prodrug Implants
    • 12.3.1.3. Polymeric Drug Delivery
    • 12.3.1.4. Targeted Drug Delivery
  • 12.3.2. Gene Delivery Systems
    • 12.3.2.1. Viral Gene Delivery
      • 12.3.2.1.1. Adenovirus Vector
      • 12.3.2.1.2. Lentivirus Vector
      • 12.3.2.1.3. Retrovirus Vector
      • 12.3.2.1.4. Adeno-associated Virus Vector
      • 12.3.2.1.5. Sendai Virus Vector
      • 12.3.2.1.6. Herpes Simplex Virus Vector
      • 12.3.2.1.7. Others
    • 12.3.2.2. Non-viral Gene Delivery
      • 12.3.2.2.1. Natural Organic Compounds
      • 12.3.2.2.2. Physical Methods
      • 12.3.2.2.3. Chemical Methods
    • 12.3.2.3. Combined Hybrid System
• 12.4. Market Value Forecast, by Route of Administration, 2017-2031
  • 12.4.1. Oral
  • 12.4.2. Injectable
  • 12.4.3. Inhalation
  • 12.4.4. Transdermal
  • 12.4.5. Ocular
  • 12.4.6. Nasal
  • 12.4.7. Topical
• 12.5. Market Value Forecast, by Application, 2017-2031
  • 12.5.1. Infectious Diseases
  • 12.5.2. Oncology
  • 12.5.3. Ophthalmology
  • 12.5.4. Urology
  • 12.5.5. Diabetes
  • 12.5.6. CNS
  • 12.5.7. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Delivery System
  • 12.7.2. By Route of Administration
  • 12.7.3. By Application
  • 12.7.4. By Country/Sub-region

13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Delivery System, 2017-2031
  • 13.3.1. Drug Delivery Systems
    • 13.3.1.1. Intrauterine Implants
    • 13.3.1.2. Prodrug Implants
    • 13.3.1.3. Polymeric Drug Delivery
    • 13.3.1.4. Targeted Drug Delivery
  • 13.3.2. Gene Delivery Systems
    • 13.3.2.1. Viral Gene Delivery
      • 13.3.2.1.1. Adenovirus Vector
      • 13.3.2.1.2. Lentivirus Vector
      • 13.3.2.1.3. Retrovirus Vector
      • 13.3.2.1.4. Adeno-associated Virus Vector
      • 13.3.2.1.5. Sendai Virus Vector
      • 13.3.2.1.6. Herpes Simplex Virus Vector
      • 13.3.2.1.7. Others
    • 13.3.2.2. Non-viral Gene Delivery
      • 13.3.2.2.1. Natural Organic Compounds
      • 13.3.2.2.2. Physical Methods
      • 13.3.2.2.3. Chemical Methods
    • 13.3.2.3. Combined Hybrid System
• 13.4. Market Value Forecast, by Route of Administration, 2017-2031
  • 13.4.1. Oral
  • 13.4.2. Injectable
  • 13.4.3. Inhalation
  • 13.4.4. Transdermal
  • 13.4.5. Ocular
  • 13.4.6. Nasal
  • 13.4.7. Topical
• 13.5. Market Value Forecast, by Application, 2017-2031
  • 13.5.1. Infectious Diseases
  • 13.5.2. Oncology
  • 13.5.3. Ophthalmology
  • 13.5.4. Urology
  • 13.5.5. Diabetes
  • 13.5.6. CNS
  • 13.5.7. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Delivery System
  • 13.7.2. By Route of Administration
  • 13.7.3. By Application
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Delivery System, 2017-2031
  • 14.3.1. Drug Delivery Systems
    • 14.3.1.1. Intrauterine Implants
    • 14.3.1.2. Prodrug Implants
    • 14.3.1.3. Polymeric Drug Delivery
    • 14.3.1.4. Targeted Drug Delivery
  • 14.3.2. Gene Delivery Systems
    • 14.3.2.1. Viral Gene Delivery
      • 14.3.2.1.1. Adenovirus Vector
      • 14.3.2.1.2. Lentivirus Vector
      • 14.3.2.1.3. Retrovirus Vector
      • 14.3.2.1.4. Adeno-associated Virus Vector
      • 14.3.2.1.5. Sendai Virus Vector
      • 14.3.2.1.6. Herpes Simplex Virus Vector
      • 14.3.2.1.7. Others
    • 14.3.2.2. Non-viral Gene Delivery
      • 14.3.2.2.1. Natural Organic Compounds
      • 14.3.2.2.2. Physical Methods
      • 14.3.2.2.3. Chemical Methods
    • 14.3.2.3. Combined Hybrid System
• 14.4. Market Value Forecast, by Route of Administration, 2017-2031
  • 14.4.1. Oral
  • 14.4.2. Injectable
  • 14.4.3. Inhalation
  • 14.4.4. Transdermal
  • 14.4.5. Ocular
  • 14.4.6. Nasal
  • 14.4.7. Topical
• 14.5. Market Value Forecast, by Application, 2017-2031
  • 14.5.1. Infectious Diseases
  • 14.5.2. Oncology
  • 14.5.3. Ophthalmology
  • 14.5.4. Urology
  • 14.5.5. Diabetes
  • 14.5.6. CNS
  • 14.5.7. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Delivery System
  • 14.7.2. By Route of Administration
  • 14.7.3. By Application
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Novartis AG
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Delivery System Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Amgen Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Delivery System Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Oxford BioMedica plc.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Delivery System Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. SIBIONO
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Delivery System Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Shanghai Sunway Biotech Co., Ltd.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Delivery System Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. F. Hoffmann-La Roche Ltd.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Delivery System Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Pfizer, Inc.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Delivery System Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Bayer AG
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Delivery System Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Johnson & Johnson Services, Inc.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Delivery System Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Becton, Dickinson and Company
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Delivery System Portfolio
    • 15.3.10.3. SWOT Analysis
    • 15.3.10.4. Financial Overview
    • 15.3.10.5. Strategic Overview
  • 15.3.11. AstraZeneca plc
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Delivery System Portfolio
    • 15.3.11.3. SWOT Analysis
    • 15.3.11.4. Financial Overview
    • 15.3.11.5. Strategic Overview
  • 15.3.12. Baxter International, Inc.
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Delivery System Portfolio
    • 15.3.12.3. SWOT Analysis
    • 15.3.12.4. Financial Overview
    • 15.3.12.5. Strategic Overview
  • 15.3.13. Boston Scientific Corporation
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Delivery System Portfolio
    • 15.3.13.3. SWOT Analysis
    • 15.3.13.4. Financial Overview
    • 15.3.13.5. Strategic Overview
  • 15.3.14. GenVivo, Inc.
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Delivery System Portfolio
    • 15.3.14.3. SWOT Analysis
    • 15.3.14.4. Financial Overview
    • 15.3.14.5. Strategic Overview